Zymeworks Inc. Common Stock Cash Flow Conversion Efficiency
Zymeworks Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Zymeworks Inc. Common Stock (ZYME) has a cash flow conversion efficiency ratio of -0.098x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.41 Million) by net assets ($320.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Zymeworks Inc. Common Stock (2014–2024)
Cash flow conversion efficiency of Zymeworks Inc. Common Stock from 2014 to 2024. This chart illustrates how Zymeworks Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Zymeworks Inc. Common Stock (ZYME) stock price for real-time trading data and today's change.
Zymeworks Inc. Common Stock Cash Flow Conversion Ratio Explained
Zymeworks Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Zymeworks Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zymeworks Inc. Common Stock ranked by their cash flow conversion efficiency. Also see ZYME market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OVH Groupe SAS
PA:OVH
|
10.219x |
|
Melco Resorts & Entertainment Ltd
NASDAQ:MLCO
|
-0.046x |
|
Aerospace Auto
SHG:600151
|
0.024x |
|
Jiangsu Toland Alloy Co Ltd
SHE:300855
|
0.049x |
|
Guangdong Mingyang Electric Co. Ltd. A
SHE:301291
|
N/A |
|
Fidelis Insurance Holdings Limited
NYSE:FIHL
|
0.102x |
|
Flight Centre Travel Group Ltd
AU:FLT
|
-0.051x |
|
Sopharma AD
WAR:SPH
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Zymeworks Inc. Common Stock (2014–2024)
The table below shows the annual cash flow conversion efficiency of Zymeworks Inc. Common Stock from 2014 to 2024. Review Zymeworks Inc. Common Stock free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $338.77 Million | $-110.04 Million | -0.325x | -27.63% |
| 2023-12-31 | $464.81 Million | $-118.30 Million | -0.255x | -187.06% |
| 2022-12-31 | $492.96 Million | $144.11 Million | 0.292x | +137.84% |
| 2021-12-31 | $249.09 Million | $-192.45 Million | -0.773x | -109.18% |
| 2020-12-31 | $409.92 Million | $-151.40 Million | -0.369x | -10.86% |
| 2019-12-31 | $245.68 Million | $-81.85 Million | -0.333x | -348.72% |
| 2018-12-31 | $180.49 Million | $24.18 Million | 0.134x | +7021.35% |
| 2017-12-31 | $116.43 Million | $219.00K | 0.002x | +100.05% |
| 2016-12-31 | $9.00 Million | $-35.25 Million | -3.915x | -222.11% |
| 2015-12-31 | $18.24 Million | $-22.17 Million | -1.216x | -589.12% |
| 2014-12-31 | $39.78 Million | $-7.02 Million | -0.176x | -- |
About Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. … Read more